MRK vs NEOG
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
MRK shows neutral fundamentals based on deterministic rules. Financial strength is weak (F-Score 3/9). Mixed signals with both opportunities and risks present.
NEOG presents a stark contrast between a deteriorating income statement and a robust balance sheet. The Piotroski F-Score of 2/9 indicates significant fundamental weakness and poor operational trends, further evidenced by a -69.94% profit margin and declining revenue. However, the company maintains a strong liquidity position with a current ratio of 3.92 and low leverage (Debt/Equity 0.38), and the stock is currently trading at book value (P/B 0.99). While recent price momentum is bullish, the lack of earnings growth suggests this is a speculative turnaround play rather than a value investment.
Compare Another Pair
Related Comparisons
MRK vs NEOG: Head-to-Head Comparison
This page compares Merck & Co., Inc. (MRK) and Neogen Corporation (NEOG) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.